Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy
Last week, Lyell Immunopharma Inc. (NASDAQ:LYEL) agreed to acquire ImmPACT Bio USA Inc., a privately owned clinical-stage biotechnology company.
Lyell has prioritized its pipeline to focus resources on its most differentiated CAR T-cell clinical programs, including IMPT-314 following the close of the acquisition and LYL119.
Also Read: Lyell Immunopharma Shares Plunge On One Patient Death In CAR-T Cell Therapy Cancer Trial
Lyell announced the discontinuation of the development of LYL797 to focus on the Phase 1 clinical trial of LYL119, which is expected to initiate enrollment of patients with platinum-resistant ovarian cancer or relapsed/refractory endometrial cancer this year or early next year.
The LYL845 tumor-infiltrating lymphocyte (TIL) program is also being discontinued, as the clinical data in patients with advanced melanoma did not meet pre-determined criteria for continued development.
Its next-generation TIL …
Full story available on Benzinga.com